BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 14582821)

  • 1. Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy.
    Goldberg A; Confino-Cohen R
    Ann Allergy Asthma Immunol; 2003 Oct; 91(4):405-10. PubMed ID: 14582821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
    Goldberg A; Yogev A; Confino-Cohen R
    Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy.
    Gorska L; Chelminska M; Kuziemski K; Skrzypski M; Niedoszytko M; Damps-Konstanska I; Szymanowska A; Siemińska A; Wajda B; Drozdowska A; Jutel M; Jassem E
    Int Arch Allergy Immunol; 2008; 147(3):241-5. PubMed ID: 18594155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.
    Goldberg A; Confino-Cohen R
    J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrarush venom desensitization after systemic reactions during conventional venom immunotherapy.
    Oren E; Chegini S; Hamilos DL
    Ann Allergy Asthma Immunol; 2006 Nov; 97(5):606-10. PubMed ID: 17165267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
    Ruëff F; Wenderoth A; Przybilla B
    J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy of venom immunotherapy.
    Hafner T; DuBuske L; Kosnik M
    Ann Allergy Asthma Immunol; 2008 Feb; 100(2):162-5. PubMed ID: 18320918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bee venom immunotherapy - how early is it effective?
    Goldberg A; Confino-Cohen R
    Allergy; 2010 Mar; 65(3):391-5. PubMed ID: 19839973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A modified ultra-rush-protocol of allergen immunotherapy in children and adolescents with insect venom allergy].
    Steiss JO; Hüls G; Gortner L; Lindemann H
    Klin Padiatr; 2004; 216(2):79-82. PubMed ID: 15106079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis.
    Bernstein JA; Kagen SL; Bernstein DI; Bernstein IL
    Ann Allergy; 1994 Nov; 73(5):423-8. PubMed ID: 7978535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rush hymenoptera venom immunotherapy is efficacious and safe.
    Pasaoglu G; Sin BA; Misirligil Z
    J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venom immunotherapy: tolerance to a 3-day protocol of rush-immunotherapy.
    Díez Gómez ML; Quirce Gancedo S; Juliá de Páramo B
    Allergol Immunopathol (Madr); 1995; 23(6):277-84. PubMed ID: 8579006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simple 3-day "rush" venom immunotherapy protocol: documentation of safety.
    Kalogeromitros D; Makris M; Koti I; Chliva C; Mellios A; Avgerinou G; Theoharides TC
    Allergol Immunopathol (Madr); 2010; 38(2):69-73. PubMed ID: 19853357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis.
    Verburg M; Oldhoff JM; Klemans RJ; Lahey-de Boer A; de Bruin-Weller MS; Röckmann H; Sanders C; Bruijnzeel-Koomen CA; Pasmans SG; Knulst AC
    Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):192-6. PubMed ID: 26549336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venom immunotherapy for preventing allergic reactions to insect stings.
    Boyle RJ; Elremeli M; Hockenhull J; Cherry MG; Bulsara MK; Daniels M; Oude Elberink JN
    Cochrane Database Syst Rev; 2012 Oct; 10(10):CD008838. PubMed ID: 23076950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile of hymenoptera venom immunotherapy (VIT) in monosensitized patients: lack of new sensitization to nontreated insect venom.
    Spoerl D; Bircher AJ; Scherer K
    J Investig Allergol Clin Immunol; 2011; 21(1):22-7. PubMed ID: 21370719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific ultrarush desensitization in Hymenoptera venom-allergic patients.
    Schiavino D; Nucera E; Pollastrini E; De Pasquale T; Buonomo A; Bartolozzi F; Lombardo C; Roncallo C; Patriarca G
    Ann Allergy Asthma Immunol; 2004 Apr; 92(4):409-13. PubMed ID: 15104191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse reactions in venom immunotherapy protocols: conventional versus ultra-rush.
    Selcuk A; Baysan A; Yesillik S; Demirel F; Kartal O; Gulec M; Musabak U; Sener O
    Ann Med; 2022 Dec; 54(1):2321-2325. PubMed ID: 36111408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
    Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
    Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population.
    Roesch A; Boerzsoenyi J; Babilas P; Landthaler M; Szeimies RM
    J Dtsch Dermatol Ges; 2008 Apr; 6(4):292-7. PubMed ID: 18042250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.